Amarillo Biosciences is working with global partners to conduct clinical studies to establish the safety and efficacy of low-dose interferon-alpha given in the form of orally dissolving lozenges to treat a number of significant human diseases, including influenza and hepatitis C.
ARMAQ Amarillo Biosciences, Inc (OTCMRKTS: ARMAQ) Stock Message Board
10220 | Sponsor | 03/29/2024 9:03:45 AM |
Be the first to post on ARMAQ Amarillo Biosciences, Inc ARMAQ